Veradermics, Incorporated
MANE
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.83B
Close$
$0.62
99.3% downside
Current Fair Value
99.3% downsideOvervalued by 99.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.83 Billion |
|---|---|
| Enterprise Value | $3.66 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.38 |
| Beta | 0.58 |
| Outstanding Shares | 37,340,290 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -62.55 |
|---|---|
| PEG | -16.41 |
| Price to Sales | - |
| Price to Book Ratio | 9.03 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
June 3, 2026
EPS Estimate
$-0.64
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 11, 2026
EPS Estimate
$-0.68
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 12.88%▲ 12.88% |
|---|---|
| Total Invested | $1.63B |
| Investors Holding | 81▲ 81.00% |
ESG Score
No data
About Veradermics, Incorporated
21 employees
CEO: Reid Waldman Veradermics, Incorporated operates as a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. Th...